Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Capital Expenditures (2018 - 2025)

Serina Therapeutics' Capital Expenditures history spans 6 years, with the latest figure at $13000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures rose 333.33% year-over-year to $13000.0; the TTM value through Sep 2025 reached $64000.0, up 117.16%, while the annual FY2024 figure was $22000.0, 50.0% down from the prior year.
  • Capital Expenditures for Q3 2025 was $13000.0 at Serina Therapeutics, down from $46000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $119000.0 in Q3 2023 and bottomed at -$390000.0 in Q4 2023.
  • The 3-year median for Capital Expenditures is $13000.0 (2025), against an average of -$27142.9.
  • The largest annual shift saw Capital Expenditures plummeted 97.48% in 2024 before it surged 333.33% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at -$390000.0 in 2023, then skyrocketed by 101.28% to $5000.0 in 2024, then soared by 160.0% to $13000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Capital Expenditures are $13000.0 (Q3 2025), $46000.0 (Q2 2025), and $5000.0 (Q4 2024).